Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 3, 2024Nature MedicineOpen Access

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXavier LeleuInsermCHCyrille HulinSciences Po BordeauxJLJérôme LambertInserm

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Leleu et al. (2024) studied this question.

synapsesocial.com/papers/68e665f2b6db6435875f2059https://doi.org/10.1038/s41591-024-03050-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients2023 · 102 citations
  2. 2Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma2008 · 1,914 citations
  3. 3Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma2023 · 589 citations
  4. 4How I treat multiple myeloma in geriatric patients2023 · 72 citations
  5. 5Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy2014 · 51 citations